
Incyte (INCY) Stock Forecast & Price Target
Incyte (INCY) Analyst Ratings
Bulls say
Incyte is making smart strategic moves to enhance its drug delivery methods, with its ENHANZE technology through Halozyme, creating a subQ alternative for its leading drug Jakafi, increasing convenience for patients while maintaining its market share. The recent CMS settlement and EU label approval for Opzelura also add to Incyte's stronghold in the dermatology market, making it a credible growth bridge through Jakafi LOE. Overall, with a strong pipeline and promising clinical trial results, Incyte is well-positioned for future success in the small-molecule drug market.
Bears say
Incyte is currently overvalued, with a DCF-based valuation resulting in a lower 12-month price objective of $140 per share. Risks for the company include slower market uptake, delays in approvals for late-stage candidates, failure to generate positive data for ongoing programs, and potential long-term equity dilution risk. This could be due to factors such as lower-than-expected growth from current assets and unexpected successes from the pipeline.
This aggregate rating is based on analysts' research of Incyte and is not a guaranteed prediction by Public.com or investment advice.
Incyte (INCY) Analyst Forecast & Price Prediction
Start investing in Incyte (INCY)
Order type
Buy in
Order amount
Est. shares
0 shares